Articles related to MIGRAINES/HEADACHES

Updated AAN and AHS guidance outlines when to initiate preventive migraine therapy, how to select treatments based on efficacy and tolerability, and how to tailor management for special populations and comorbidities.

This review outlines a practical approach to headache imaging, emphasizing that MRI is preferred over CT in most nonemergent settings, while contrast-enhanced MRI should be reserved for specific red-flag scenarios such as malignancy, immunosuppression, focal neurologic deficits, intracranial pressure disorders, infection, and trigeminal autonomic cephalalgias.

The FDA authorized Avulux lenses as a nonpharmacologic adjunct for migraine-associated light sensitivity in patients aged 12 years and older, supported by clinical data showing reduced photophobia and exploratory signals of headache pain improvement in some users.

Multimodal MRI analysis identified two distinct migraine subgroups in a 111-patient cohort, with one cluster showing widespread cortical-subcortical connectivity changes and lower cortical volumes tied to greater disease burden and disability.

A systematic review of 43 randomized controlled trials found high-certainty evidence that multiple CGRP-targeted therapies reduced monthly migraine headache days by approximately 2 days versus placebo in adults with chronic migraine.

The American College of Physicians Performance Measurement Committee reviewed the single MIPS quality measure tied to migraine and declined to support it, citing outdated guideline basis, missing exclusions, and lack of physician-level testing.